Phase 2 CAPTIVATE Study @cityofhope

Phase 2 CAPTIVATE Study @cityofhope

obr

4 months
12 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, elaborates on outcomes from the Phase 2 CAPTIVATE study investigating the BTK inhibitor ibrutinib plus venetoclax in the 1st line treatment of chronic lymphocytic lymphoma (CLL).
Up Next Autoplay